3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Gastrointestinal
1
Conditions
Mesothelioma, Malignant
2
Severe combined immunodeficiency with sensitivity to ionizing radiation
1
Interventions
Carboplatin
334
Pemetrexed
275
Cisplatin
227
Paclitaxel
193
pembrolizumab
178
Erlotinib Hydrochloride
173
Docetaxel
154
Gemcitabine
126
Nivolumab
112
Bevacizumab
112
Radiotherapy
84
Etoposide
68
durvalumab
62
atezolizumab
59
Ipilimumab
51
Radiosurgery
49
osimertinib
41
130-nm albumin-bound paclitaxel
40
Afatinib
39
Gefitinib
38
Cetuximab
38
Albumin-Bound Paclitaxel
37
Taxes
32
Vinorelbine
29
Radiation
29
Topotecan
28
Drug Therapy
25
Crizotinib
23
Platinum
21
Dexamethasone
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
amatuximab
×
Thoracic
×
Clear all
NCT00738582
2022-09-22
Amatuximab
Morphotek
Phase 2
Completed
89 enrolled
12 charts
NCT02357147
2020-03-17
ARTEMIS
Morphotek
Phase 2
Terminated
124 enrolled
10 charts